Dimerix Stock

Dimerix EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Dimerix (DXB.AX) as of Sep 5, 2026 is -34.01 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -52.75 % — a change of -35.54% (higher).

EBIT/Assets

-34.01 %

YoY

-35.54%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Dimerix is 2026 -34.01 % . Operating Income to Assets Ratio (EBIT/Assets) of Dimerix was 2025 -52.75 % . It decreases by -35.54% higher compared to the previous year.

The Dimerix EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-45.70 AUD
Jan 1, 2019
-58.42 AUD
Jan 1, 2020
-43.26 AUD
Jan 1, 2021
-67.11 AUD
Jan 1, 2022
-63.31 AUD
Jan 1, 2023
-77.41 AUD
Jan 1, 2024
-52.75 AUD
Jan 1, 2025
-34.01 AUD
The Dimerix EBIT/Assets history
YEAREBIT/AssetsYoY
-34.01 %-35.54%
-52.75 %-31.85%
-77.41 %+22.27%
-63.31 %-5.66%
-67.11 %+55.13%
-43.26 %-25.95%
-58.42 %+27.84%
-45.70 %-25.37%
-61.23 %+20.84%
-50.67 %+159.58%
-19.52 %-57.06%
-45.45 %
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Operating Income to Assets Ratio (EBIT/Assets) of Dimerix is -34.01 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of Dimerix changed from -52.75 % to -34.01 %, representing a -35.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Dimerix since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Dimerix with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

Profitability — Dimerix

All Key Metrics — Dimerix